Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

As cases of monkeypox continue to rise, Moderna Inc (NASDAQ: MRNA) is probably working on its platform towards finding a vaccine shot against the disease. The company announced plans to explore potential vaccines for monkeypox at a "preclinical level," according to an .

This Famed Company Is Working On A Potential Monkeypox Vaccine

The World Health Organization said on Tuesday there have been 131 confirmed monkeypox cases and 106 further suspected cases since the first was reported on May 7 outside the countries where it usually spreads.

Moderna testing potential monkeypox vaccines

Moderna Inc. MRNA, -4.72% tweeted Monday afternoon that it is "investigating potential monkeypox vaccines at a preclinical level." Several stocks of companies that are developing or have smallpox or monkeypox vaccines and treatments jumped in trading on Monday as more people have become aware of the cluster of cases in Europe.

Moderna says it will start developing monkeypox vaccine

Pharmaceutical company Moderna Therapeutics Inc (NASDAQ:MRNA) is testing potential vaccines against monkeypox, as the number of cases continues to rise in the UK and elsewhere. Moderna is said to be conducting pre-clinical trials for a monkeypox vaccine, according to Reuters.

Moderna Inc conducting moneypox vaccine trials, report

Pfizer

The Food and Drug Administration said Monday an advisory panel would meet June 15 to discuss use of the vaccines developed by Pfizer and German partner BioNTech, as well as the one developed by Moderna MRNA, -6.77% ,  in children aged 6 months to four years old.

Coronavirus Update: FDA panel to review Pfizer and Moderna vaccines for children aged six month to 4 years on June 15

Despite a steep Moderna stock crash this year, the longtime biotech executive has amassed a $4.6 billion fortune.

Billionaire Moderna CEO Stéphane Bancel Pledges Stock Options Worth $355 Million To Undisclosed Charitable Causes

Booking Hlds

Corteva Inc

Electronic Arts

Intel

Molina Healthcare

T. Rowe Price Group

The S&P 500 is down more than 15% in 2022. That makes it difficult to find the best blue-chip stocks to buy to keep the bear market away.

7 Best Blue-Chip Stocks to Buy Now for Safety

Despite good regulatory news for both companies, and encouraging clinical results reported from one, investor reaction was muted.

Why Moderna and Pfizer Stocks Lagged the Market Today

The FDA said it will complete its review of Pfizer and Moderna's applications within days of each other.

FDA panel sets June 15 meeting on Pfizer, Moderna Covid vaccines for infants and toddlers

Exelixis

Vertex Pharmaceuticals

3 Stocks That Could Make You a Fortune Over the Next 10 Years

Novavax

Better Buy: Moderna or Novavax?

Different dynamics are at work for these vaccine stocks.

Why Pfizer Stock Is Rising Today While Moderna and Novavax Are Sliding

Pfizer, BioNTech and Moderna are experiencing a post-vaccine hangover on Wall Street this year.

Pfizer and Moderna saved lives during Covid-19. So why are their stocks crumbling?

Here's How Moderna Could Top $450 Again

Dell Technologies

GoPro

Honeywell

Micron Technology

Seagate Technology Holdings PLC

History has repeatedly shown that steep corrections are the perfect time to shop for undervalued stocks. These are among the most undervalued stocks to invest in now.

The 7 Most Undervalued Stocks to Buy After the Sell-Off

On Tuesday, Moderna Inc. ( MRNA , Financial) CEO Stéphane Bancel made a bold prediction at the company's first in-person Science and Technology Day since 2019, saying mRNA technology has the unique opportunity “to change medicine forever.”

Moderna CEO: Our Technology Has the Opportunity to Change Medicine

Advanced Micro Devices

Off and on the price chart these three blue-chip tech stocks look great to buy following earnings beats and attractive price charts. The post 3 Blue-Chip Tech Stocks to Buy Now appeared first on InvestorPlace.

3 Blue-Chip Tech Stocks to Buy Now

CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24th at 9:15 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.

Moderna to Present at the UBS 2022 Global Healthcare Conference

Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.

Moderna (MRNA) Stock Rises 4%: What's Behind the Upside?

But it's not the stock that investors should be worried about.

Moderna Just Made a $700,000 Mistake

Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / The nonprofit scientific research organization IAVI and Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant screenings are soon to start for a Phase I clinical trial of an mRNA HIV vaccine antigen (mRNA-1644) at the Center for Family Health Research (CFHR) in Kigali, Rwanda, and The Aurum Institute in Tembisa, South Africa. The IAVI-sponsored trial, IAVI G003, builds on progress in HIV vaccine research.

IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program

Moderna, Inc. (NASDAQ:MRNA ) Annual Science and Technology Day Conference May 17, 2022 9:00 AM ET Company Participants Stéphane Bancel - CEO Melissa Moore - Chief Scientific Officer, Scientific Affairs Jean Sung - Senior Director, Respiratory Delivery Phil White - Vice President, CMC Lifecycle Management Conference Call Participants Stéphane Bancel Well, good morning, everybody. Good afternoon, if you're alive.

Moderna, Inc. (MRNA) Annual Science and Technology Day Conference (Transcript)

Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery Moderna's 5th Annual Science and Technology Day presentations highlight continued focus, safety and innovation of our intramuscular lipid nanoparticles (LNPs) delivery system in vaccines CAMBRIDGE, MA / ACCESSWIRE / May 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, today announced new research findings as part of the Company's fifth annual Science and Technology Day. Moderna continues to highlight investments in the expansion of the utility of the mRNA platform, characterization of the Company's vaccines, biodistribution of vaccines, and using clinical data to predict vaccine dosing.

Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day

Moderna Inc. (NASDAQ:MRNA) has been strong since it rolled out COVID-19 vaccines. The demand for vaccines has started to slow down.

What next as Moderna finds support at $130?

CRISPR Therapeutics

These two companies have been southbound lately.

News for Moderna Stock (MRNA)